Stock DNA
Pharmaceuticals & Biotechnology
JPY 20,774 Million (Small Cap)
7.00
NA
0.02%
0.76
15.76%
0.63
Revenue and Profits:
Net Sales:
15,503 Million
(Quarterly Results - Jun 2025)
Net Profit:
462 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.05%
0%
-0.05%
6 Months
3.09%
0%
3.09%
1 Year
-11.28%
0%
-11.28%
2 Years
16.88%
0%
16.88%
3 Years
10.21%
0%
10.21%
4 Years
-10.56%
0%
-10.56%
5 Years
-24.87%
0%
-24.87%
Fuso Pharmaceutical Industries Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.25%
EBIT Growth (5y)
32.52%
EBIT to Interest (avg)
14.69
Debt to EBITDA (avg)
1.50
Net Debt to Equity (avg)
0.38
Sales to Capital Employed (avg)
1.08
Tax Ratio
33.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.92%
ROE (avg)
4.77%
Valuation key factors
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
0.52
EV to EBIT
8.55
EV to EBITDA
5.45
EV to Capital Employed
0.65
EV to Sales
0.58
PEG Ratio
0.08
Dividend Yield
0.02%
ROCE (Latest)
7.63%
ROE (Latest)
6.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
15,503.00
14,622.00
6.03%
Operating Profit (PBDIT) excl Other Income
1,238.00
1,728.00
-28.36%
Interest
70.00
38.00
84.21%
Exceptional Items
77.00
80.00
-3.75%
Consolidate Net Profit
462.00
632.00
-26.90%
Operating Profit Margin (Excl OI)
38.50%
78.70%
-4.02%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 6.03% vs 8.25% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -26.90% vs 31.94% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
60,563.00
55,407.00
9.31%
Operating Profit (PBDIT) excl Other Income
5,958.00
3,695.00
61.24%
Interest
161.00
171.00
-5.85%
Exceptional Items
-8,660.00
-39.00
-22,105.13%
Consolidate Net Profit
-3,288.00
1,377.00
-338.78%
Operating Profit Margin (Excl OI)
68.20%
35.50%
3.27%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 9.31% vs 8.61% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -338.78% vs -14.21% in Mar 2024
About Fuso Pharmaceutical Industries Ltd. 
Fuso Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






